Brentuximab vedotin - Seagen/Takeda Oncology
Alternative Names: Adcetris; Anti-CD30-MMAE; Anti-CD30-monoclonal-antibody-cAC10-auristatin-E-conjugate; Auristatin-E-anti-CD30-monoclonal-antibody-cAC10-conjugate; Brentuximab; cAC10-vcMMAE; MMAE-anti-CD30; SGN-35Latest Information Update: 18 Oct 2024
At a glance
- Originator Seattle Genetics; Stanford University
- Developer Bristol-Myers Squibb; Celgene Corporation; Dana-Farber Cancer Institute; Fondazione Italiana Linfomi; Fox Chase Cancer Center; Immune Tolerance Network; Lymphoma Academic Research Organisation; Massachusetts General Hospital; National Cancer Institute (USA); National Institute of Allergy and Infectious Diseases; Seagen; Seattle Genetics; Stanford University; Takeda; Takeda Oncology; UNC Lineberger Comprehensive Cancer Center; Washington University School of Medicine
- Class Antineoplastics; Antiretrovirals; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies; Oligopeptides; Skin disorder therapies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Anaplastic large cell lymphoma; Hodgkin's disease; Mycosis fungoides; Peripheral T-cell lymphoma; Primary cutaneous anaplastic large cell lymphoma; T-cell lymphoma
- Preregistration Diffuse large B cell lymphoma
- Phase II Adult T-cell leukaemia-lymphoma; Diffuse scleroderma; Germ cell cancer; Malignant-mesothelioma; Mastocytosis; Non-Hodgkin's lymphoma; Sezary syndrome; Solid tumours
- Phase I HIV-1 infections
- No development reported Graft-versus-host disease
- Discontinued Leukaemia; Multiple myeloma; Systemic lupus erythematosus
Most Recent Events
- 10 Oct 2024 Seagen terminates a phase II trial in Hodgkin's disease (Combination therapy, In children, In adolescents, In adults, In the elderly, Treatment-naive) in USA, Australia, Czech Republic, Italy, Poland, Spain (IV) due to sufficient data collection (NCT03646123)
- 31 Jul 2024 Preregistration for Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (IV)
- 30 Jul 2024 FDA assigns PDUFA action date of March 2025 for Brentuximab vedotin for Diffuse large b-cell lymphoma (Second-line therapy or greater, Combination therapy) in the US